India, Aug. 5 -- Kymera Therapeutics, Inc. (KYMR) reported on Wednesday second quarter financial results, reflecting narrower net loss, primarily driven by a higher collaboration revenue. The company also provided business highlights and upcoming milestones.
Company Profile
Kymera Therapeutics is a clinical-stage biotechnology company developing oral targeted protein degraders for immune-inflammatory diseases. Its pipeline includes KT-621 for atopic dermatitis and asthma, KT-579 for Lupus and other autoimmune diseases, and KT-485, partnered with Sanofi, for inflammatory disorders.
FY26 Second Quarter Highlights
Net loss attributable to common stockholders narrowed to $61.21 million, or $0.62 per share from loss of $76.61 million, or $0....